Skip to main content
. 2020 Oct 6;19(4):173–179. doi: 10.18502/cjn.v19i4.5544

Table 1.

Clinical and demographic characteristic

Variable Group
Positive MOG (n = 12) Negative MOG (n = 59) All patients (n = 71) P
Age (year) 30.5 [23.5-33.7] 33.0 [29.0-40.0] 33.0 [28.0-39.0] 0.208
Gender
     Men 2 (16.7) 17 (28.8) 19 (26.8) 0.494
     Women 10 (83.3) 42 (71.2) 52 (73.2)
Family history 2 (16.7) 3 (5.1) 5 (7.0) 0.196
EDSS score at onset 2.0 [1.5-2.5] 2.0 [2.0-2.5] 2.0 [2.0-2.5] 0.537
Other autoimmune disease 1 (8.3) 4 (6.8) 6 (8.5) 0.999
Relapse 2 (16.7) 13 (22.0) 15 (21.1) 0.731
Time of relapse (month) 16.0 [12] 12.0 [7.0-24.0] 12.0 [8.0-24.0] 0.946
Last EDSS score 1.5 [1.0-2.0] 1.5 [1.0-2.0] 1.5 [1.0-2.0] 0.743
First symptoms
     Sensory 1 (8.3) 11 (18.6) 12 (16.9) 0.460
     Motor 11 (91.7) 48 (81.4) 59 (83.1)
Motor presentations
     Paraparesis 10 (90.9) 33 (68.8) 43 (72.9) 0.259
     Quadriparesis 1 (9.1) 15 (31.3) 16 (27.1)
     Urinary incontinence 2 (16.7) 6 (10.2) 8 (11.3) 0.615
     Visual 3 (25.0) 15 (25.4) 18 (25.4) 0.999
     Abnormal MRI 5 (41.7) 36 (61.0) 41 (57.7) 0.216
     Follow duration (month) 9.0 [3.0-12.0] 12.0 [3.0-24.0] 12.0 [3.0-24.0] 0.452

Data are presented as number (percent) and median [interquartile range (IQR)]

MOG: Myelin oligodendrocyte glycoprotein; EDSS: Expanded Disability Status Scale; MRI: Magnetic resonance imaging